R
Ryuichi Morishita
Researcher at Osaka University
Publications - 696
Citations - 31441
Ryuichi Morishita is an academic researcher from Osaka University. The author has contributed to research in topics: Hepatocyte growth factor & Genetic enhancement. The author has an hindex of 86, co-authored 676 publications receiving 29651 citations. Previous affiliations of Ryuichi Morishita include Brigham and Women's Hospital & Stanford University.
Papers
More filters
Journal ArticleDOI
The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014)
Kazuaki Shimamoto,Katsuyuki Ando,Toshiro Fujita,Naoyuki Hasebe,Jitsuo Higaki,Masatsugu Horiuchi,Yutaka Imai,Tsutomu Imaizumi,Toshihiko Ishimitsu,Masaaki Ito,Sadayoshi Ito,Hiroshi Itoh,Hiroshi Iwao,Hisashi Kai,Kazuomi Kario,Naok Kashihara,Yuhei Kawano,Shokei Kim-Mitsuyama,Genjiro Kimura,Katsuhiko Kohara,Issei Komuro,Hiroo Kumagai,Hideo Matsuura,Katsuyuki Miura,Ryuichi Morishita,Mitsuhide Naruse,Koichi Node,Yusuke Ohya,Hiromi Rakugi,Ikuo Saito,Shigeyuki Saitoh,Kazuyuki Shimada,Tatsuo Shimosawa,Hiromichi Suzuki,Kouichi Tamura,Norio Tanahashi,Takuya Tsuchihashi,Makoto Uchiyama,Shinichiro Ueda,Satoshi Umemura +39 more
TL;DR: Kazuaki SHIMAMOTO, Katsuyuki ANDO, Toshiro FUJITA, Naoyuki HASEBE, Jitsuo HIGAKI, Masatsugu HORIUCHI, Yutaka IMAI, Tsutomu IMAIZUMI, Toshihiko ISHIMITSU, Masaaki ITO, Sadayoshi ITO and Hiroshi ITOH are presented.
Journal ArticleDOI
Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
H. E. Von Der Leyen,Gary H. Gibbons,Ryuichi Morishita,Neil P. Lewis,Lunan Zhang,Masatoshi Nakajima,Yasufumi Kaneda,John P. Cooke,Victor J. Dzau +8 more
TL;DR: Direct evidence is provided that NO is an endogenous inhibitor of vascular lesion formation in vivo (by inhibiting smooth muscle cell proliferation and migration) and the possibility of ec-NOS transfection as a potential therapeutic approach to treat neointimal hyperplasia is suggested.
Journal ArticleDOI
The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer
Masatoshi Nakajima,Howard G. Hutchinson,Masahiko Fujinaga,Wataru Hayashida,Ryuichi Morishita,Lunan Zhang,Masatsugu Horiuchi,Richard E. Pratt,Victor J. Dzau +8 more
TL;DR: Results suggest that the AT2 receptor exerts an antiproliferative effect, counteracting the growth action of AT1 receptor.
Journal ArticleDOI
In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction.
Ryuichi Morishita,Toshiko Sugimoto,Motokuni Aoki,Iwao Kida,Naruya Tomita,Atsushi Moriguchi,Kazuhiro Maeda,Yoshiki Sawa,Yasufumi Kaneda,Jitsuo Higaki,Toshio Ogihara +10 more
TL;DR: The first successful in vivo transfer of NFκB decoy oligodeoxynucleotides to reduce the extent of myocardial infarction following reperfusion is reported, providing a new therapeutic strategy for myocardia infarctions.
Journal ArticleDOI
Hepatocyte growth factor gene therapy of liver cirrhosis in rats.
Takahiro Ueki,Yasufumi Kaneda,Hiroko Tsutsui,Kenji Nakanishi,Yoshiki Sawa,Ryuichi Morishita,Kunio Matsumoto,Toshikazu Nakamura,Hiroshi Takahashi,Eizo Okamoto,Jiro Fujimoto +10 more
TL;DR: In a rat model of lethal liver cirrhosis produced by dimethylnitrosamine administrations, repeated transfections of the human HGF gene into skeletal muscles induced a high plasma level of human as well as enodogenous rat HGF, and tyrosine phosphorylation of the c–Met/HGF receptor suppressed the increase of transforming growth factor–β1 and produced the complete resolution of fibrosis in the cirrhotic liver.